Russell Investments Group Ltd. reduced its position in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 12.4% during the 3rd quarter, HoldingsChannel reports. The fund owned 782,981 shares of the company’s stock after selling 110,519 shares during the period. Russell Investments Group Ltd.’s holdings in Zoetis were worth $54,726,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently modified their holdings of ZTS. BlackRock Inc. increased its stake in shares of Zoetis by 10.8% in the 2nd quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock valued at $2,833,453,000 after purchasing an additional 3,845,869 shares in the last quarter. State Street Corp raised its holdings in Zoetis by 1.8% in the 2nd quarter. State Street Corp now owns 19,667,723 shares of the company’s stock worth $1,413,323,000 after purchasing an additional 343,322 shares during the period. Bank of America Corp DE boosted its position in Zoetis by 7.3% during the first quarter. Bank of America Corp DE now owns 4,831,652 shares of the company’s stock worth $571,150,000 after purchasing an additional 327,313 shares in the last quarter. Deutsche Bank AG boosted its position in Zoetis by 5.8% during the second quarter. Deutsche Bank AG now owns 5,851,737 shares of the company’s stock worth $420,506,000 after purchasing an additional 319,709 shares in the last quarter. Finally, Van ECK Associates Corp boosted its position in Zoetis by 7.7% during the second quarter. Van ECK Associates Corp now owns 4,252,140 shares of the company’s stock worth $305,559,000 after purchasing an additional 303,395 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several analysts have commented on ZTS shares. Stifel Nicolaus dropped their price objective on Zoetis from $85.00 to $80.00 and set a “hold” rating on the stock in a report on Thursday, August 20th. TD Cowen reduced their target price on Zoetis from $104.00 to $94.00 and set a “buy” rating for the company in a research note on Tuesday, August 25th. Zacks Research upgraded Zoetis from a “strong sell” rating to a “hold” rating in a research report on Monday, October 26th. Cantor Fitzgerald set a $94.00 target price on Zoetis in a research report on Tuesday, August 25th. Finally, Morgan Stanley dropped their price target on shares of Zoetis from $85.00 to $82.00 and set an “overweight” rating on the stock in a research note on Thursday, October 29th. Eight equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $101.25.
Read Our Latest Stock Report on ZTS
Zoetis Stock Down 0.2%
Shares of NYSE ZTS opened at $83.65 on Monday. The firm has a market cap of $33.99 billion, a price-to-earnings ratio of 14.23, a price-to-earnings-growth ratio of 1.21 and a beta of 0.67. The company’s 50-day simple moving average is $76.28 and its 200-day simple moving average is $91.56. The company has a quick ratio of 1.40, a current ratio of 2.35 and a debt-to-equity ratio of 2.51. Zoetis Inc. has a 52-week low of $68.77 and a 52-week high of $132.49.
Zoetis (NYSE:ZTS – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported $1.75 earnings per share for the quarter, topping the consensus estimate of $1.51 by $0.24. The firm had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 26.15% and a return on equity of 85.90%. The company’s revenue for the quarter was down 1.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.70 EPS. Equities analysts predict that Zoetis Inc. will post 6.29 EPS for the current fiscal year.
Zoetis Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 1st. Shareholders of record on Friday, October 30th will be paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 2.5%. The ex-dividend date is Friday, October 30th. Zoetis’s payout ratio is 36.05%.
Zoetis Company Profile
Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish. The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.
Featured Articles
- Five stocks we like better than Zoetis
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
